WEDNESDAY, June 25, 2025 (HealthDay News) -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early type ...
Hemoglobin A1c (HbA1c) remains a cornerstone in the diagnosis and monitoring of diabetes, and its proper use is central to implementing the 2023 American Diabetes Association (ADA) guidelines. While ...
All 3 doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40. HealthDay News — The oral small-molecule glucagon-like peptide-1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results